
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vac... Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California. Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.55 | -12.8504672897 | 4.28 | 4.37 | 3.26 | 118072 | 3.63609193 | CS |
4 | -1.27 | -25.4 | 5 | 5.4 | 3.26 | 164078 | 4.18954364 | CS |
12 | 1.43 | 62.1739130435 | 2.3 | 5.885 | 2.16 | 219335 | 3.95502873 | CS |
26 | 1.175 | 45.988258317 | 2.555 | 5.885 | 1.95 | 183156 | 3.354337 | CS |
52 | -2.52 | -40.32 | 6.25 | 6.5 | 1.6 | 197896 | 3.07324293 | CS |
156 | -2.27 | -37.8333333333 | 6 | 40.98 | 1.6 | 162324 | 9.86614268 | CS |
260 | -2.27 | -37.8333333333 | 6 | 40.98 | 1.6 | 162324 | 9.86614268 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales